



May 16, 2022

VIA EDGAR

Michael Davis  
Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, DC 20549

**Re: Landos Biopharma, Inc.  
Registration Statement on Form S-3; File No. 333-263836**

**Acceleration Request**

**Requested Date: Wednesday, May 18, 2022**

**Requested Time: 4:00 p.m. Eastern Time**

Dear Mr. Davis:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the "**Registrant**") hereby requests that the Securities and Exchange Commission (the "**Commission**") take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-263836) (the "**Registration Statement**") to become effective on Wednesday, May 18, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the "**Staff**").

Once the Registration Statement has been declared effective, please orally confirm that event with Katie Kazem of Cooley LLP, counsel to the Registrant, at (703) 456-8043, or in her absence, Madison Jones at (202) 728-7087.

Very truly yours,

**LANDOS BIOPHARMA, INC.**

By: /s/ Tim M. Mayleben

Tim M. Mayleben

Chief Executive Officer